|
Oncogenes and Tumor Suppressors
Citations 411-420 of 795 total displayed.
|
Past content
(since May 2000):
|
RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation
- Joachim Schwäble, Chunaram Choudhary, Christian Thiede, Lara Tickenbrock, Bülent Sargin, Claudia Steur, Maike Rehage, Annika Rudat, Christian Brandts, Wolfgang E. Berdel, Carsten Müller-Tidow, and Hubert Serve
Blood 2005; 105: 2107-2114.
[Abstract]
[Full text]
[PDF]
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML
- Tomoya Maeda, Fumiharu Yagasaki, Maho Ishikawa, Naoki Takahashi, and Masami Bessho
Blood 2005; 105: 2115-2123.
[Abstract]
[Full text]
[PDF]
Therapy-related acute myeloid leukemia–like MLL rearrangements are induced by etoposide in primary human CD34+ cells and remain stable after clonal expansion
- Jolanta Libura, Diana J. Slater, Carolyn A. Felix, and Christine Richardson
Blood 2005; 105: 2124-2131.
[Abstract]
[Full text]
[PDF]
Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells
- Delin Zhu, Chen Feng Qi, Herbert C. Morse, III, Siegfried Janz, and Freda K. Stevenson
Blood 2005; 105: 2135-2137.
[Abstract]
[Full text]
[PDF]
Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability
- Michele L. Criscuoli, Mai Nguyen, and Brian P. Eliceiri
Blood 2005; 105: 1508-1514.
[Abstract]
[Full text]
[PDF]
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor
- Nikolas von Bubnoff, Darren R. Veach, Heiko van der Kuip, Walter E. Aulitzky, Jana Sänger, Petra Seipel, William G. Bornmann, Christian Peschel, Bayard Clarkson, and Justus Duyster
Blood 2005; 105: 1652-1659.
[Abstract]
[Full text]
[PDF]
Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors
- Liliana Guedez, Antonio Martinez, Shumei Zhao, Angelica Vivero, Stefania Pittaluga, Maryalice Stetler-Stevenson, Mark Raffeld, and William G. Stetler-Stevenson
Blood 2005; 105: 1660-1668.
[Abstract]
[Full text]
[PDF]
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species
- Jeong H. Kim, Stephanie C. Chu, Jessica L. Gramlich, Yuri B. Pride, Emily Babendreier, Dharminder Chauhan, Ravi Salgia, Klaus Podar, James D. Griffin, and Martin Sattler
Blood 2005; 105: 1717-1723.
[Abstract]
[Full text]
[PDF]
Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival
- Kyu-Tae Kim, Kristin Baird, Joon-Young Ahn, Paul Meltzer, Michael Lilly, Mark Levis, and Donald Small
Blood 2005; 105: 1759-1767.
[Abstract]
[Full text]
[PDF]
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
- Prince George, Purva Bali, Srinivas Annavarapu, Anna Scuto, Warren Fiskus, Fei Guo, Celia Sigua, Gautam Sondarva, Lynn Moscinski, Peter Atadja, and Kapil Bhalla
Blood 2005; 105: 1768-1776.
[Abstract]
[Full text]
[PDF]
|
|
